These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10365327)

  • 1. [Concentric changes in the visual field associated with GABA-mimetic antiepileptic agents].
    Nordmann JP; Baulac M; Van Egroo C
    J Fr Ophtalmol; 1999 May; 22(4):418-22. PubMed ID: 10365327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptomatic and asymptomatic visual loss in patients taking vigabatrin.
    Daneshvar H; Racette L; Coupland SG; Kertes PJ; Guberman A; Zackon D
    Ophthalmology; 1999 Sep; 106(9):1792-8. PubMed ID: 10485552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe visual-field constriction and side-effects of GABA-mimetic antiepileptic agents.
    Baulac M; Nordmann JP; Lanoé Y
    Lancet; 1998 Aug; 352(9127):546. PubMed ID: 9716066
    [No Abstract]   [Full Text] [Related]  

  • 4. [Study of visual field and vigabatrin treatment in children].
    Pelosse B; Momtchilova M; Roubergue A; Doummar D; Billette de Villemeur T; Laroche L
    J Fr Ophtalmol; 2001 Dec; 24(10):1075-80. PubMed ID: 11913238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vigabatrin and alterations of the visual field].
    Argumosa A; Herranz JL; Arteaga R; Barrasa J; Calles L; Armijo J
    Rev Neurol; 1999 Apr 16-30; 28(8):741-5. PubMed ID: 10363313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal.
    Newman WD; Tocher K; Acheson JF
    Eye (Lond); 2002 Sep; 16(5):567-71. PubMed ID: 12194070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Visual field changes secondary to vigabatrin treatment].
    Mauri-Llerda JA; Iñiguez C; Tejero-Juste C; Santos-Lasaosa S; Escalza-Cortina I; Ascaso-Puyuelo J; Abad-Alegría F; Morales-Asín F
    Rev Neurol; 2000 Dec 16-31; 31(12):1104-8. PubMed ID: 11205539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin.
    Mackenzie R; Klistorner A
    BMJ; 1998 Jan; 316(7126):233. PubMed ID: 9468717
    [No Abstract]   [Full Text] [Related]  

  • 9. Binasal visual field defects are not specific to vigabatrin.
    Gonzalez P; Sills GJ; Parks S; Kelly K; Stephen LJ; Keating D; Dutton GN; Brodie MJ
    Epilepsy Behav; 2009 Nov; 16(3):521-6. PubMed ID: 19815465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication.
    Best JL; Acheson JF
    Eye (Lond); 2005 Jan; 19(1):41-4. PubMed ID: 15094729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing.
    Blackwell N; Hayllar J; Kelly G
    BMJ; 1997 Jun; 314(7095):1694. PubMed ID: 9193313
    [No Abstract]   [Full Text] [Related]  

  • 12. A pharmacogenetic exploration of vigabatrin-induced visual field constriction.
    Kinirons P; Cavalleri GL; Singh R; Shahwan A; Acheson JF; Wood NW; Goldstein DB; Sisodiya SM; Doherty CP; Delanty N
    Epilepsy Res; 2006 Aug; 70(2-3):144-52. PubMed ID: 16675198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Visual field disturbances in epileptic patients treated with vigabatrin (sevril)].
    Gross-Tsur V; Lahat E; Banin E; Shahar E; Shalev R
    Harefuah; 2002 Mar; 141(3):247-9, 315. PubMed ID: 11944216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of vigabatrin on visual fields and electrophysiological tests in patients with epilepsy].
    Mrugacz M; Bakunowicz-Łazarczyk A
    Klin Oczna; 2003; 105(5):326-8. PubMed ID: 14746191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visual field constriction is not limited to children treated with vigabatrin.
    Wohlrab G; Boltshauser E; Schmitt B; Schriever S; Landau K
    Neuropediatrics; 1999 Jun; 30(3):130-2. PubMed ID: 10480207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is visual field constriction in epilepsy patients treated with vigabatrin reversible?
    Schmidt T; Rüther K; Jokiel B; Pfeiffer S; Tiel-Wilck K; Schmitz B
    J Neurol; 2002 Aug; 249(8):1066-71. PubMed ID: 12195456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Vigabatrin and visual field defects. A Danish material with evaluation of different screening methods].
    Riise P; Fledelius HC; Rogvi-Hansen Bà
    Ugeskr Laeger; 2003 Mar; 165(10):1034-8. PubMed ID: 12645411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity.
    Lawthom C; Smith PE; Wild JM
    Ophthalmology; 2009 Mar; 116(3):565-71. PubMed ID: 19168223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is reduced ornithine-δ-aminotransferase activity the cause of vigabatrin-associated visual field defects?
    Sorri I; Brigell MG; Mályusz M; Mahlamäki E; de Meynard C; Kälviäinen R
    Epilepsy Res; 2010 Nov; 92(1):48-53. PubMed ID: 20850272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: a prospective study.
    Schmitz B; Schmidt T; Jokiel B; Pfeiffer S; Tiel-Wilck K; Rüther K
    J Neurol; 2002 Apr; 249(4):469-75. PubMed ID: 11967655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.